116666-63-8

Basic information

• Product Name: MIBEFRADIL
• Synonyms: (1s-cis)-orid;2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-aceticaci;6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenylester,dihydrochl;ro40-5967/001;Mibefradil diHCl;Mibefradil hydrate dihydrochloride;Ro 40-5967 hydrate, (1S,2S)-2-[2[[3-(2-Benzimidazolylpropyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate hydrate dihydrochloride;Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1S-cis)-
• CAS NO: 116666-63-8
• Molecular Formula: C29H40Cl2FN3O3
• Molecular Weight: 568.5506032
• Mol File: 116666-63-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 128℃
• Boiling Point: 647.6°Cat760mmHg
• Flash Point: 345.5°C
• Appearance: white/solid
• Density: g/cm³
• Vapor Pressure: 1.17E-16mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: H2O: 24 mg/mL, soluble
• PKA: 4.8; 5.5(at 25℃)
• Stability: Hygroscopic
• CAS DataBase Reference: MIBEFRADIL(CAS DataBase Reference)
• NIST Chemistry Reference: MIBEFRADIL(116666-63-8)
• EPA Substance Registry System: MIBEFRADIL(116666-63-8)

Safety Data

• WGK Germany: 3
• RTECS: AI8977250
• Hazardous Substances Data: 116666-63-8(Hazardous Substances Data)

Usage

Description

Posicor was launched in Argentina, Azerbaijan, Brazil, the Chile, Czech Republic, Denmark, Germany, Ireland, Kazakhstan, the Netherlands, Norway, Peru, the Philippines, Switzerland, Thailand, Turkmenistan, the UK, the US and Venezuela for use in hypertension. It can be assembled in five steps from 4-(1-benzyloxy-Nmethylformamido) butyric acid with o-phenylenediamine and isobutylchloroformate. Posicor binds to calcium channels in a manner that overlaps the Verapamil, SR-33557 and Diltiazem binding site without effecting the dihydropyridine binding site. Thus it blocks a wide variety of calcium channels with selectivity for T-type followed sequentially by L-type. There is also some calcium agonist activity along with sodium and potassium channel activity. It is chemically distinct from the other calcium antagonists (first member of a new catagory of tetralol calcium antagonists). It has the ability to lower heart rate with no negative inotropic effects and is as effective as Amlodipine and more effective than Diltiazem for the treatment of mild to moderate hypertension. Serious drug interactions are possible because Posicor inhibits both CYP2D6 and CYP3A4.

Originator

Roche (Switzerland)

Uses

Different sources of media describe the Uses of 116666-63-8 differently. You can refer to the following data:
1. Vasodilator.
2. Mibefradil has been used as a T-type calcium channel blocker in various cells. It has also been used to reduce apoptosis of retinal ganglion cells (RGC) in EphB2-Fc.

Therapeutic Function

Coronary vasodilator

Biochem/physiol Actions

Mibefradil is a tetralol derivative and nondihydropyridine calcium channel blocker. It blocks long-type (L-type) calcium channels. It blocks mildly the Purkinje-type (P-type) calcium channels in Purkinje neurons.

InChI:InChI=1/C29H38FN3O3.2ClH/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26;;/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32);2*1H/t28-,29-;;/m0../s1

Upstream product

• 38870-89-2 Methoxyacetyl chloride 
• 116666-60-5 (1S,2S)-2-[2-{[3-(1H-benzimidazol-2-yl)propyl]methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol 

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

Tetrahydronaphthalene derivatives and medicaments containing them

-